Your shopping cart is currently empty

7α-Hydroxy-4-cholesten-3-one is an intermediate in bile acid synthesis from cholesterol, a PXR agonist, and a biomarker for bile acid loss and diseases related to defective bile acid biosynthesis. It is also the physiological substrate for [CYP8B1].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $289 | In Stock | In Stock | |
| 5 mg | $612 | - | In Stock | |
| 10 mg | $892 | - | In Stock |
| Description | 7α-Hydroxy-4-cholesten-3-one is an intermediate in bile acid synthesis from cholesterol, a PXR agonist, and a biomarker for bile acid loss and diseases related to defective bile acid biosynthesis. It is also the physiological substrate for [CYP8B1]. |
| In vitro | 7α-Hydroxy-4-cholesten-3-one is a key intermediate in the bile acid synthesis pathway. Cytochrome P450 7A1 introduces a 7α-hydroxy group to cholesterol, and 3β-hydroxysteroid dehydrogenase then oxidizes and isomerizes the 3-hydroxy group and the Δ5,6-double bond, forming 7α-Hydroxy-4-cholesten-3-one. The absence of P450 27A1 downstream increases its concentration [1]. |
| In vivo | 7α-Hydroxy-4-cholesten-3-one significantly influences the hepatic enzyme CYP7A1 activity under steady-state conditions and during rapid diurnal fluctuations in rats. Moreover, its serum levels exhibit a marked diurnal rhythm. |
| Synonyms | 7-hydroxy-4-cholesten-3-one |
| Molecular Weight | 400.64 |
| Formula | C27H44O2 |
| Cas No. | 3862-25-7 |
| Smiles | [H][C@@]12CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@H](O)CC2=CC(=O)CC[C@]12C |
| Relative Density. | 1.03 g/cm3 (Predicted) |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (199.68 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Corn Oil: 3.3 mg/mL (8.24 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.